An unfavourable environment weighs on ONCOMED PHARMS.INCO., which sees a downgrade to Negative
The independent financial analyst theScreener just requalified the general evaluation of ONCOMED PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was USD 1.02 and its target price was estimated at USD 0.53.OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company. The company has four anti-cancer therapeutic candidates: Navicixizumab, which is a bispecific monoclonal antibody that targets and inhibits both Delta-like ligand 4, and vascular endothelial growth factor; Anti-TIGIT, which is an inhibitory receptor that stops T-cells from attacking certain tumor cells; GITRL-Fc, which is engineered using a single-gene, linkerless trimer technology that is designed to enable activation of glucocorticoid-induced tumor necrosis factor receptor-related protein; and Rosmantuzumab, which is a monoclonal antibody targeting the RSPO-LGR cancer stem cell pathway.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.